Compare Biogen Inc (BIIB) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Williams Companies Inc — how do they compare? Biogen Inc trades at $196 (market cap $28.34B), while Williams Companies Inc trades at $74.39 (market cap $92.92B). The key difference: Williams Companies Inc is far larger — about 3.3× Biogen Inc's market cap, and Williams Companies Inc pays a 2.76% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | WMB | |
|---|---|---|
Market Cap | $28.34B | $92.92B |
Sector | Health | Energy |
52-Week High | $216.63 | $79.40 |
52-Week Low | $122.68 | $56.51 |
Enterprise Value | $30.62B | $122.31B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Williams Companies (WMB) trades at $74.46, down 0.75% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported revenue of $11.95 billion in 2025 with a net income margin of 23.4%, and recent news highlights a $5.34 billion Blackstone-led investment to accelerate power projects. Valuation ratios include a P/E of 32.66 and P/B of 7.03, reflecting premium pricing relative to historical levels.
WMB presents a positive outlook with a consensus price target of $85.67, indicating 15% upside potential, supported by stable cash flows and strategic investments in energy infrastructure. Risks include exposure to natural gas price volatility and high debt levels, but the company's fee-based contracts and growth initiatives provide a buffer against market swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
